Mesenchymal–Epithelial Transition in Mesenchymal Tumors: An Immunophenotypic Characterization

Introduction Mesenchymal–epithelial transition (MET) is essential for plasticity but remains insufficiently investigated in mesenchymal tumors. While regulatory mechanisms of epithelial–mesenchymal transition (EMT)/MET programs have been studied in individual sarcoma types, their role across mesenchymal neoplasms remains unclear. This study aimed to investigate MET-related phenotypes in mesenchymal tumors and their relevance to tumor characterization and nodal metastasis. Materials and Methods A total of 527 mesenchymal tumor samples representing benign, intermediate, and malignant entities were analyzed, including paired primary and metastatic samples from seven sarcomas with nodal metastasis. Immunohistochemical expression of the EMT-related transcription factors SLUG, TWIST1, and ZEB1, together with E-cadherin, was evaluated. Plasticity profiles were defined. Results MET-related phenotypes were identified in 90.3% of mesenchymal tumors, most commonly the intermediate MET low profile (71.5%), followed by epithelial-like MET high (18.8%) and mesenchymal-like MET neg (9.7%) profiles. Their distribution did not significantly differ by biological behavior and was comparable to that of the malignant control groups. TWIST1 expression was significantly more frequent in intermediate-to-malignant than in benign tumors. SLUG loss and ZEB1 loss were particularly associated with nerve sheath differentiation. In sarcomas with nodal metastases, no significant differences in marker expression were observed within the limited paired cohort between primary and metastatic lesions. Conclusions Epithelial–mesenchymal plasticity is widespread in mesenchymal tumors and most commonly manifests as an intermediate phenotype rather than a fully epithelial or mesenchymal state. Plasticity profiles appear largely independent of conventional tumor categories and nodal metastatic behavior, while selected marker patterns may reflect differentiation lineage and have potential clinical relevance.

Authors

Institutions

Publication Details

Journal
International Journal of Surgical Pathology
Published
2026-11-17
DOI
https://doi.org/10.1177/10668969261504391
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mesenchymal–Epithelial Transition in Mesenchymal Tumors: An Immunophenotypic Characterization

Kemal Kösemehmetoğlu, Altan Kavuncuoğlu
International Journal of Surgical Pathology
Cancer Cells and Metastasis
article

Mesenchymal–Epithelial Transition in Mesenchymal Tumors: An Immunophenotypic Characterization

Kemal Kösemehmetoğlu, Altan Kavuncuoğlu
article en

Abstract

Introduction Mesenchymal–epithelial transition (MET) is essential for plasticity but remains insufficiently investigated in mesenchymal tumors. While regulatory mechanisms of epithelial–mesenchymal transition (EMT)/MET programs have been studied in individual sarcoma types, their role across mesenchymal neoplasms remains unclear. This study aimed to investigate MET-related phenotypes in mesenchymal tumors and their relevance to tumor characterization and nodal metastasis. Materials and Methods A total of 527 mesenchymal tumor samples representing benign, intermediate, and malignant entities were analyzed, including paired primary and metastatic samples from seven sarcomas with nodal metastasis. Immunohistochemical expression of the EMT-related transcription factors SLUG, TWIST1, and ZEB1, together with E-cadherin, was evaluated. Plasticity profiles were defined. Results MET-related phenotypes were identified in 90.3% of mesenchymal tumors, most commonly the intermediate MET low profile (71.5%), followed by epithelial-like MET high (18.8%) and mesenchymal-like MET neg (9.7%) profiles. Their distribution did not significantly differ by biological behavior and was comparable to that of the malignant control groups. TWIST1 expression was significantly more frequent in intermediate-to-malignant than in benign tumors. SLUG loss and ZEB1 loss were particularly associated with nerve sheath differentiation. In sarcomas with nodal metastases, no significant differences in marker expression were observed within the limited paired cohort between primary and metastatic lesions. Conclusions Epithelial–mesenchymal plasticity is widespread in mesenchymal tumors and most commonly manifests as an intermediate phenotype rather than a fully epithelial or mesenchymal state. Plasticity profiles appear largely independent of conventional tumor categories and nodal metastatic behavior, while selected marker patterns may reflect differentiation lineage and have potential clinical relevance.

International Journal of Surgical Pathology
Hacettepe University (TR)
Good health and well-being
Cancer Cells and Metastasis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon